https://orcid.org/0000-0002-4594-5337
Figures & data
Figure 1 Consort diagram and listing of reasons for early Ra223 discontinuation. One hundred and six of 198 patients (53.5%) did not receive 6 cycles of Ra223, and disease progression was the most common reason for early treatment discontinuation in those patients.
Figure 2 Distribution of the number of Ra223 cycles administered overall, and when comparing the number of Ra223 cycles given in patients supervised by medical versus radiation oncologists. There was no significant difference in the distribution of Ra223 cycles administered under the supervision of medical oncologists (Med Onc) versus radiation oncologists (Rad Onc). *“All patients” includes patients administered Ra223 by medical oncologists (n=100), radiation oncologists (n=94), and uro-oncologists (n=4).
Table 1 Patient Characteristics
Table 2 Baseline Laboratory And Radiological Findings, And ESAS Scores
Table 3 Biochemical Response Rates
Figure 3 Kaplan–Meier overall survival analysis from the first dose of Ra223. In the entire cohort of patients, the actuarial median overall survival from the first dose of Ra223 was 13.3 months. Seventy patients had died, 128 patients were censored. Dashed lines: 95% CI.
Figure 4 Comparison of the overall survival of patients completing Ra223 therapy (6 cycles) versus patients with early treatment discontinuation (1–5 cycles). Log-rank testing revealed a significant (p<0.0001) overall survival benefit of patients completing Ra223 therapy compared to men receiving 1–5 treatments only, with an actuarial median survival time of 18.7 versus 8.1 months, respectively.
Table 4 Multivariable Logistic Regression Analysis Of 1–5 Cycles Versus 6 Cycles Of Ra223
Table 5 Multivariable Cox Proportional Hazards Model Of Overall Survival (Including 1–5 Cycles Versus 6 Cycles Of Treatment)
Table 6 Multivariable Cox Proportional Hazards Model Of Overall Survival (Excluding 1–5 Cycles Versus 6 Cycles Of Treatment)